Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Esperion (GB:0IIM)
LSE:0IIM
Holding GB:0IIM?
Track your performance easily
0IIM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.58 - $3.86
Previous CloseN/A
Volume10.92K
Average Volume (3M)35.76K
Market Cap
$461.06M
Enterprise Value$736.50M
Total Cash (Recent Filing)$211.58M
Total Debt (Recent Filing)$1.02M
Price to Earnings (P/E)―
Beta3.57
Next Earnings
Feb 27, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding197,035,170
10 Day Avg. Volume7,567
30 Day Avg. Volume35,763
Standard Deviation0.28
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.52
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.60
Enterprise Value/Revenue2.49
Enterprise Value/Gross Profit10.08
Enterprise Value/Ebitda-13.08
Forecast
1Y Price Target
$6.86Price Target Upside198.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Esperion News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe new royalty agreement with OMERS Life Sciences removes a significant and onerous obligation from the balance sheet and should improve cash flows for the company.
International ExpansionExpansion opportunities for Esperion's growth include partnerships outside the U.S., such as an NDA submission in Japan, a partnership in Israel, and a filing for approval in Canada.
Regulatory And Product DevelopmentThe Nexletol and Nexlizet labels were expanded to include a cardiovascular risk reduction indication in statin intolerant patients, increasing the addressable population to about 70 million patients in the US.
Bears Say
CompetitionAn emerging set of competing late-stage assets with encouraging data to-date in the already crowded LDL-C space presents a challenge.
Financial PerformanceEsperion had a challenging 3Q with total revenues slightly missing expectations and sales of bempedoic acid falling short by 10%.
Pipeline And ExclusivityA lack of a mid/late stage pipeline is an overhang as an end of decade loss of exclusivity looms.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.99% Insiders
18.40% Mutual Funds
0.02% Other Institutional Investors
71.03% Public Companies and Individual Investors
0IIM FAQ
What was Esperion’s price range in the past 12 months?
Esperion lowest share price was $1.58 and its highest was $3.85 in the past 12 months.
What is Esperion’s market cap?
Esperion’s market cap is $461.06M.
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Feb 27, 2025 which is in 43 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on Nov 07, 2024. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.175 by $0.025.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is -0.14.
How many shares outstanding does Esperion have?
Esperion has 197,035,170 shares outstanding.
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.175. Following the earnings report the stock price went down -3.204%.
Which hedge fund is a major shareholder of Esperion?
Currently, no hedge funds are holding shares in GB:0IIM
---
Esperion Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.86 (198.26% Upside)
$6.86 (198.26% Upside)
Blogger Sentiment
Bullish
GB:0IIM Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $44.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-25.82%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
41.94%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
---
0IIM Company Deck
---
0IIM Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Esperion has shown strong prescription growth and expanded payer access, both domestically and internationally. While facing some financial headwinds due to contract updates, the company is on track for future growth with a strengthened financial position.Read More>---
0IIM Stock 12 Month Forecast
Average Price Target
$6.86
▲(198.26% Upside)
Technical Analysis
Amarin
―
Omeros
―
Aurinia Pharmaceuticals
―
Aclaris Therapeutics
―
Xeris Pharmaceuticals
―
Pfizer
―
Esperion
―
Best Analysts Covering 0IIM
1 Year
1 Year Success Rate
9/23 ratings generated profit
1 Year Average Return
+41.46%
reiterated a buy rating 10 months ago
Copying Thomas Shrader's trades and holding each position for 1 Year would result in 39.13% of your transactions generating a profit, with an average return of +41.46% per trade.
---